Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zelicapavir in RSV Infection in Children
NCT07482657Phase 2Recruiting
- Sponsor
- Enanta Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zelicapavir in respiratory syncytial virus infection (RSV), sponsored by Enanta Pharmaceuticals. Started Jul 2026; status: recruiting.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07482657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07482657.